- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Prostate Cancer | Clinical
Roundtable Discussion: Hutson Explores When and How Clinicians Are Using Cabazitaxel in mCRPC
July 23, 2021
During a Targeted Oncology Case-Based Roundtable event, Thomas Hutson, DO, PharmD, discussed the case of a patient with metastatic castration-resistant prostate cancer.
TITAN Shows Better Quality of Life With Apalutamide Vs Placebo in mCSPC
July 22, 2021
Neeraj Agarwal, MD, discusses the health-related quality of life and patient-reported outcomes in the TITAN trial of apalutamide versus placebo patients with metastatic castration-sensitive prostate cancer.
Adding 177Lu-PSMA-617 to Standard of Care Significantly Prolongs Survival in mCRPC
July 20, 2021
In patients with progressive prostate-specific membrane antigen positive metastatic castration-resistant prostate cancer receiving treatment in the phase 3 VISION trial, the addition of the targeted radioligand therapy 177Lu-PSMA-617 to standard of care led to a nearly 40% reduction in the risk of death versus SOC alone.
Cabazitaxel Shows Improved Efficacy Compared With Androgen Receptor in Metastatic CRPC
July 16, 2021
During a Targeted Oncology Case-Based Roundtable event, A. Oliver Sartor, MD, reviewed the case of a 75-year-old man with metastatic castration-resistant prostate cancer.
Lymph Node Invasion in Prostate Cancer May Be Highly Predictable With Ga-68 PSMA PET
July 15, 2021
A study has shown that Ga-68 PSMA PET imaging predicted lymph node invasion in patients with prostate cancer at a higher specificity and higher positive predictive value compared with 3 nomograms at predicting lymph node invasion.
Sequencing Shows Potential for Identifying Multiple Biomarkers in mCRPC with MSH6 Mutation
July 13, 2021
Sequencing of over 5,000 cases of patients with metastatic castration resistant prostate cancer showed potential for identifying multiple biomarkers in MSH6-mutated cases.
Barata Identifies Options for Nonmetastatic CRPC With Relevant Trial Data
July 09, 2021
Based on clinical trial data, apalutamide, enzalutamide, and darolutamide are all viable treatment options for nonmetastatic castration resistant prostate cancer.
Safety Profile of LuPSMA Therapy in mCRPC
July 07, 2021
Dr Andrew J. Armstrong reviews the safety of LuPSMA therapy as compared to cabazitaxel as seen in the phase 2 TheraP trial and comments on sequencing strategies for patients with metastatic castration-resistant prostate cancer.
Patient Selection of LuPSMA Therapy in mCRPC
July 07, 2021
An expert in prostate cancer comments on the appropriate patient population for Lutetium-177 PSMA-617 therapy for the management of metastatic castration-resistant prostate cancer.
Phase 3 VISION Trial in PSMA-Positive mCRPC
July 07, 2021
Dr Andrew J. Armstrong reviews the phase 3 VISION trial evaluating the use of LuPSMA therapy in patients with progressive PSMA-positive metastatic castrate-resistant prostate cancer.